vimarsana.com
Home
Live Updates
Trastuzumab Plus Pertuzumab Provides Sustained iDFS Benefit in HER2+ Breast Cancer : vimarsana.com
Trastuzumab Plus Pertuzumab Provides Sustained iDFS Benefit in HER2+ Breast Cancer
A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.
Related Keywords
Valencia ,
Carabobo ,
Venezuela ,
Spain ,
Antonio Llombart Cussac ,
University Hospital Arnau De Vilanova ,
Oncology Service ,
Medical Oncology Service ,
Her2 Positive Early Breast Cancer ,
Chemotherapy Free Regimen ,
Btrastuzumab ,
Pertuzumab ,
vimarsana.com © 2020. All Rights Reserved.